Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00017225 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Combining these therapies may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with or without peripheral stem cell transplantation in treating patients who have neuroblastoma.
Condition | Intervention | Phase |
---|---|---|
Neuroblastoma |
Drug: carboplatin Drug: cisplatin Drug: cyclophosphamide Drug: dacarbazine Drug: doxorubicin hydrochloride Drug: etoposide Drug: filgrastim Drug: ifosfamide Drug: melphalan Drug: tretinoin Drug: vincristine sulfate Drug: vindesine Procedure: autologous bone marrow transplantation Procedure: conventional surgery Procedure: peripheral blood stem cell transplantation Procedure: radiation therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma |
Ages Eligible for Study: | up to 20 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Observation stratum:
Standard-risk stratum:
High-risk stratum:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Study Chair: | Frank Berthold, MD | Children's Hospital |
Study ID Numbers: | CDR0000068664, GPOH-GERMANY-NB97, EU-20102, GER-GPOH-NB97 |
Study First Received: | June 6, 2001 |
Last Updated: | August 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00017225 |
Health Authority: | United States: Federal Government |
localized resectable neuroblastoma regional neuroblastoma disseminated neuroblastoma |
stage 4S neuroblastoma recurrent neuroblastoma localized unresectable neuroblastoma |
Melphalan Dacarbazine Neuroectodermal Tumors, Primitive Vindesine Vincristine Carboplatin Cyclophosphamide Etoposide phosphate Neuroblastoma Recurrence Doxorubicin |
Neuroectodermal Tumors Ifosfamide Cisplatin Neoplasms, Germ Cell and Embryonal Tretinoin Neuroepithelioma Etoposide Neuroectodermal Tumors, Primitive, Peripheral Neoplasms, Glandular and Epithelial Isophosphamide mustard |
Neoplasms by Histologic Type Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Mitosis Modulators Neoplasms, Nerve Tissue Physiological Effects of Drugs Antimitotic Agents Antibiotics, Antineoplastic Immunosuppressive Agents |
Pharmacologic Actions Neoplasms Therapeutic Uses Tubulin Modulators Myeloablative Agonists Antineoplastic Agents, Alkylating Neoplasms, Neuroepithelial Antirheumatic Agents Antineoplastic Agents, Phytogenic Alkylating Agents |